News | May 27, 2021
Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The company plans to enter the EU markets in FY22
This marks Glenmark's first synthetic decapeptide injectable approval
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
The product patent has been already filed under fast track approval
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
Subscribe To Our Newsletter & Stay Updated
